Exelixis Inc
NASDAQ:EXEL

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
NASDAQ:EXEL
Watchlist
Price: 35.61 USD 2.24% Market Closed
Market Cap: 10.2B USD
Have any thoughts about
Exelixis Inc?
Write Note

EV/EBIT
Enterprise Value to EBIT

14.7
Current
19.5
Median
4.1
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
14.7
=
Enterprise Value
8.9B USD
/
EBIT
608.3m USD
All Countries
Close
Market Cap EV/EBIT
US
Exelixis Inc
NASDAQ:EXEL
10.1B USD 14.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -216 179.2
US
Abbvie Inc
NYSE:ABBV
314.7B USD 23.7
US
Amgen Inc
NASDAQ:AMGN
157B USD 32.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.2B USD 9.9
US
Epizyme Inc
F:EPE
94.1B EUR -502.9
AU
CSL Ltd
ASX:CSL
133.6B AUD 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 18
US
Seagen Inc
F:SGT
39.3B EUR -53.2
NL
argenx SE
XBRU:ARGX
34.5B EUR -76.6
EBIT Growth
US
Exelixis Inc
NASDAQ:EXEL
Average EV/EBIT: 21.4
14.7
284%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 179.2 N/A
US
Abbvie Inc
NYSE:ABBV
23.7
88%
US
Amgen Inc
NASDAQ:AMGN
32.9
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -502.9 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.6 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
16.6
2-Years Forward
EV/EBIT
17.8
3-Years Forward
EV/EBIT
13.6

See Also

Discover More